Opinion: Asia’s growing influence in healthcare private equity

Why Asia’s Healthcare Sector Is Capturing Global Investor Attention

For Raj Shah, Partner and Head of Healthcare at Nordic Capital, the strategic calculus for investors is becoming clearer: Asia’s profound demographic shifts represent one of the most compelling and durable growth stories in global healthcare. “We’re seeing a fundamental, secular drive,” Shah explains. “It’s not about a single trend but a convergence of an aging population, a rising burden of chronic disease, and expanding access to care, all fueled by increasing wealth. This creates a multi-decade opportunity that is largely independent of short-term economic cycles.”

Nordic Capital, a leading pan-European private equity firm with a dedicated healthcare strategy, has been progressively allocating capital toward Asian healthcare platforms. This move is underpinned by stark data: the World Health Organization projects that by 2050, the number of people aged 60 and older in the Asia-Pacific region will exceed 1.3 billion, up from approximately 600 million in 2020. Concurrently, economies like India, Indonesia, and Vietnam are experiencing rapid growth in a middle class demanding higher-quality health services. For Shah and his team, this isn’t speculative; it’s a response to measurable, irreversible demographic pressures.

Building Portfolio Resilience Through Healthcare Exposure

A key driver for this capital migration is the pursuit of portfolio resilience. Healthcare has historically demonstrated lower correlation to economic downturns compared to more cyclical sectors. During periods of inflation or recession, demand for essential medicines, medical devices, and healthcare services tends to remain inelastic. “Investors are looking for assets that can provide defensive characteristics without sacrificing growth,” Shah notes. “High-quality, innovation-driven healthcare businesses in Asia can offer this unique profile.”

This strategy involves targeting companies with strong market positions, recurring revenue models, and essential product portfolios. For instance, businesses involved in generic pharmaceutical manufacturing, contract research and development (CRO) services, or hospital management in underpenetrated markets present attractive risk-adjusted return profiles. The goal is to construct a portfolio that can weather macroeconomic volatility while participating in the region’s long-term development. Data from market analysts like GlobalData supports this, highlighting consistent healthcare expenditure growth in major Asian economies even during broader economic slowdowns.

Catalyzing Innovation to Address Localized Needs

Beyond tapping into demand, investors are keenly focused on backing innovation that solves Asia-specific challenges. Shah points to digital health, affordable diagnostic technologies, and supply chain localization as prime areas. “Innovation here often means ‘frugal innovation’—delivering high-quality outcomes at a fraction of the cost of Western equivalents,” he says. “This is where the next generation of globally competitive healthcare companies will emerge.”

The rise of telemedicine in India and Southeast Asia, accelerated by the COVID-19 pandemic, exemplifies this. Platforms that connect patients in rural areas with specialists in urban hubs are scaling rapidly, supported by widespread smartphone penetration. Similarly, advancements in genomics and personalized medicine are being adapted to address the genetic profiles prevalent in Asian populations. Nordic Capital’s approach involves providing not just capital, but operational expertise to help portfolio companies scale these innovations regionally and globally. References to reports from consultancies like McKinsey & Company underscore the potential, with Asia’s digital health market projected to reach hundreds of billions of dollars by the end of the decade.

The Path Forward: disciplined, Long-Term Capital Deployment

For Shah, success in this landscape requires deep local expertise and a long-term horizon. “You need to understand the regulatory environments, the competitive dynamics, and the cultural nuances of each market,” he emphasizes. “This is not about quick bets; it’s about building pillars of the healthcare ecosystem.” Nordic Capital’s track record includes supporting the growth of companies like Euromedic, a leading provider of diagnostic imaging services, and IBEX, a revenue cycle management services firm, applying similar principles of operational value creation.

The firm’s current focus on Asia is a calculated bet on the region’s ability to not only consume more healthcare but to become a net exporter of solutions. By investing in companies that improve access, drive efficiency, and pioneer new treatment modalities, investors like Nordic Capital aim to achieve competitive financial returns while contributing to tangible societal outcomes. As Shah concludes, “The intersection of demographic destiny, technological enablement, and policy support makes Asian healthcare a cornerstone for any investor seeking both growth and stability in the next decade.”